氧驱雾化吸入普米克令舒治疗哮喘急性发作患儿肺功能的影响
|
摘要
目的探讨哮喘急性发作患儿应用氧驱雾化吸入普米克令舒对其肺功能及临床疗效的影响。方法选取该院于2017年4月—2018年9月收治的84例哮喘急性发作患儿,将其随机分为对照组与观察组,各组42例。其中对照组予以常规治疗,观察组则在对照组的基础上加以氧驱雾化吸入普米克令舒的治疗方式,对比两组患儿的临床疗效以及肺功能指标的改善情况。结果观察组临床治疗总有效率为92.9%,对照组为71.4%,观察组总有效率明显高于对照组,差异有统计学意义(P<0.05);观察组患儿治疗前FVC、FEV_1以及PEF分别为(1.05±0.27)L、(1.59±0.51)L、(165.75±24.18)L/min,对照组患儿治疗前FVC、FEV_1以及PEF分别为(1.03±0.28)L、(1.57±0.46)L、(165.39±23.62)L/min,观察组与对照组患儿治疗前FVC、FEV_1以及PEF比较,差异无统计学意义(t=0.333 2,0.188 7,0.069 0;P>0.05)。观察组患儿治疗后FVC、FEV_1以及PEF分别为(1.95±0.46)L、(2.84±0.57)L、(198.32±30.43)L/min,对照组患儿治疗后FVC、FEV_1以及PEF分别为(1.36±0.32)L、(2.14±0.47)L、(179.26±31.05)L/min,观察组患儿治疗后FVC、FEV_1以及PEF明显高于对照组,差异有统计学意义(t=6.823 5,6.140 5,2.841 2;P<0.05)。结论针对哮喘急性发作患儿的治疗过程中,在常规治疗的基础下,加以氧驱雾化吸入普米克令舒的治疗方式可显著提升患儿的治疗效率,加快临床各项指标的消失时间,促进患儿肺功能指标的改善程度,值得临床借鉴实施。
Objective To investigate the effect of inhalation of Pulmicort Respules on the pulmonary function and clinical efficacy of children with acute asthma attack. Methods Eighty-four children with acute asthma exacerbations were enrolled in our hospital from April 2017 to September 2018. They were randomly divided into control group and observation group, with 42 cases in each group. The control group received routine treatment, and the observation group was treated with oxygen-driven aerosol inhalation of Pulmicort Respules on the basis of the control group. The clinical efficacy and improvement of lung function index were compared between the two groups. Results The total effective rate was 92.9% in the observation group and 71.4% in the control group. The total effective rate of the observation group was significantly higher than that of the control group,the difference was statistically significant(P<0.05). The FVC, FEV_1 and PEF of the observation group were(1.05±0.27)L,(1.59±0.51)L,(165.75±24.18)L/min, FVC, FEV_1 and PEF in the control group were(1.03±0.28)L,(1.57±0.46)L, and(165.39±23.62)L/min, respectively. Compared with the control group, the pre-treatment FVC, FEV_1 and PEF were compared. The difference was not statistically significant(t=0.333 2, 0.188 7, 0.069 0; P>0.05). The FVC, FEV_1 and PEF of the observation group were(1.95±0.46)L,(2.84±0.57)L and(198.32±30.43)L/min, respectively. The FVC, FEV_1 and PEF of the control group were(1.36±0.32)L,(2.14±0.47)L and(179.26±31.05)L/min, respectively. FVC, FEV_1 and PEF were significantly higher in the observation group than in the control group,the difference was statistically significant(t=6.823 5, 6.140 5, 2.841 2; P<0.05). Conclusion In the treatment of children with acute asthma attack, under the conventional treatment, the treatment of oxygenation and inhalation of Pulmicort can significantly improve the treatment efficiency of children and accelerate the disappearance of clinical indicators, to promote the improvement of lung function indicators in children, it is worthy of clinical implementation.
Objective To investigate the effect of inhalation of Pulmicort Respules on the pulmonary function and clinical efficacy of children with acute asthma attack. Methods Eighty-four children with acute asthma exacerbations were enrolled in our hospital from April 2017 to September 2018. They were randomly divided into control group and observation group, with 42 cases in each group. The control group received routine treatment, and the observation group was treated with oxygen-driven aerosol inhalation of Pulmicort Respules on the basis of the control group. The clinical efficacy and improvement of lung function index were compared between the two groups. Results The total effective rate was 92.9% in the observation group and 71.4% in the control group. The total effective rate of the observation group was significantly higher than that of the control group,the difference was statistically significant(P<0.05). The FVC, FEV_1 and PEF of the observation group were(1.05±0.27)L,(1.59±0.51)L,(165.75±24.18)L/min, FVC, FEV_1 and PEF in the control group were(1.03±0.28)L,(1.57±0.46)L, and(165.39±23.62)L/min, respectively. Compared with the control group, the pre-treatment FVC, FEV_1 and PEF were compared. The difference was not statistically significant(t=0.333 2, 0.188 7, 0.069 0; P>0.05). The FVC, FEV_1 and PEF of the observation group were(1.95±0.46)L,(2.84±0.57)L and(198.32±30.43)L/min, respectively. The FVC, FEV_1 and PEF of the control group were(1.36±0.32)L,(2.14±0.47)L and(179.26±31.05)L/min, respectively. FVC, FEV_1 and PEF were significantly higher in the observation group than in the control group,the difference was statistically significant(t=6.823 5, 6.140 5, 2.841 2; P<0.05). Conclusion In the treatment of children with acute asthma attack, under the conventional treatment, the treatment of oxygenation and inhalation of Pulmicort can significantly improve the treatment efficiency of children and accelerate the disappearance of clinical indicators, to promote the improvement of lung function indicators in children, it is worthy of clinical implementation.
引文
[1]张凤秋.特布他林雾化液、异丙托溴铵雾化液、普米克令舒联合雾化吸入治疗慢阻肺急性加重期的疗效观察[J]中国社区医师,2018,34(32):53-54.
[2]陆惠兰.大剂量的普米克令舒联合沙丁胺醇治疗急性发作期儿童重度哮喘的效果探析[J].当代医药论丛,201816(18):60-61.
[3]朱丁贤.万托林联合普米克令舒雾化吸入治疗小儿哮喘急性发作的效果及不良反应观察[J].中国现代药物应用2018,12(15):123-124.
[4]陈红霞.氧驱雾化吸入普米克令舒治疗小儿哮喘急性发作疗效及对肺功能的影响[J].临床医药文献电子杂志2018,5(50):176-177.
[5]蒋锐.普米克令舒联合万托林雾化吸入对小儿喘息型肺炎的疗效及TNF-a、HS-CRP的影响[J].黑龙江医药2018,31(3):557-558.
[6]吴瑕.普米克令舒联合吸入用复方异丙托溴铵溶液雾化吸入治疗支气管哮喘的临床疗效[J].临床合理用药杂志,2018,11(3):3-4.
[7]史敏康.布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗小儿哮喘的临床疗效分析[J].中外医疗,2018,37(29):92-93,96.
[8]朱永杰,陈俊松,陈晓轶,等.氧驱雾化吸入普米克令舒治疗小儿哮喘急性发作的效果[J].社区医学杂志,2017,15(23):55-56.
[2]陆惠兰.大剂量的普米克令舒联合沙丁胺醇治疗急性发作期儿童重度哮喘的效果探析[J].当代医药论丛,201816(18):60-61.
[3]朱丁贤.万托林联合普米克令舒雾化吸入治疗小儿哮喘急性发作的效果及不良反应观察[J].中国现代药物应用2018,12(15):123-124.
[4]陈红霞.氧驱雾化吸入普米克令舒治疗小儿哮喘急性发作疗效及对肺功能的影响[J].临床医药文献电子杂志2018,5(50):176-177.
[5]蒋锐.普米克令舒联合万托林雾化吸入对小儿喘息型肺炎的疗效及TNF-a、HS-CRP的影响[J].黑龙江医药2018,31(3):557-558.
[6]吴瑕.普米克令舒联合吸入用复方异丙托溴铵溶液雾化吸入治疗支气管哮喘的临床疗效[J].临床合理用药杂志,2018,11(3):3-4.
[7]史敏康.布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗小儿哮喘的临床疗效分析[J].中外医疗,2018,37(29):92-93,96.
[8]朱永杰,陈俊松,陈晓轶,等.氧驱雾化吸入普米克令舒治疗小儿哮喘急性发作的效果[J].社区医学杂志,2017,15(23):55-56.